Single-Agent Abemaciclib Active in Breast Cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic HER2-negative, ER-positive breast cancer remains a significant clinical challenge, particularly after progression on standard endocrine therapy and chemotherapy.
• Identifying novel therapeutic strategies is crucial for improving outcomes in this patient population.

Framework:

• This study evaluated the single-agent activity of abemaciclib, an investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.
• The phase II trial focused on patients with advanced disease refractory to established treatment regimens.

Implementation:

• Abemaciclib was administered as a single agent to women with metastatic HER2-negative, ER-positive breast cancer.
• Patient response was assessed based on objective response rate (ORR) and duration of response (DoR).

Implications:

• The findings indicate that abemaciclib possesses single-agent anti-tumor activity in this heavily pre-treated patient group.
• A 19.7% objective response rate and a 28.2% rate of responses lasting at least one year suggest potential clinical benefit for abemaciclib in this setting.